Yang Liu

Dr. Yang Liu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
QLQing Luo
Qing Luo
XSXuan Shi
Xuan Shi
JDJiarong Ding
Jiarong Ding
ZMZhenzhen Ma
Zhenzhen Ma
XCXumei Chen
Xumei Chen
YLYang Liu
Yang Liu
Background. As the malignant tumor with the highest incidence in teenagers, osteosarcoma has become a major problem in oncology research. In addition to surgical management, the pharmacotherapeutic strategy for osteosarcoma treatment is an attractive way to explore. It has been demonstrated that biochanin A has an antitumor capacity on multiple kinds of solid tumor, including osteosarcoma. But the precise mechanism of biochanin A against osteosarcoma is still needed to be discovered.Objective. To identify the potential therapeutic targets of biochanin A in treating osteosarcoma.Methods. In present study, an integrated approach including network pharmacology and molecular docking technique was conducted, which mainly comprises target prediction, network construction, gene ontology, and pathway enrichment. CCK8 test was employed to evaluate the cell viability of MG63 cells. Western-blot was used to verify the target proteins of biochanin A.Results. Ninety-six and 114 proteins were obtained as the targets of biochanin A and osteosarcoma, respectively. TP53, IGF1, JUN, BGLAP, ATM, MAPK1, ATF3, H2AFX, BAX, CDKN2A, and EGF were identified as the potential targets of biochanin A against osteosarcoma. Based on the western-blot detection, the expression of BGLAP, BAX, and ATF3 in MG63 cell line changed under the treatment of biochanin A.Conclusion. Biochanin A can effectively suppress the proliferation of osteosarcoma and regulate the expression of BGLAP, BAX, and ATF3, which may act as the potential therapeutic targets of osteosarcoma.

21 October 2025 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
YWYufeng Wang
Yufeng Wang
JBJingxia Bian
Jingxia Bian
YYYang Yuan
Yang Yuan
CLCong Li
Cong Li
YLYang Liu
Yang Liu
Background: Adolescent tibial fractures commonly lead to postoperative complications. Conventional coagulation markers (PT/APTT/FIB) lack combinatorial risk assessment. We developed an explainable ML model integrating coagulation and clinical features to predict adverse events.Methods: A retrospective cohort of 624 surgical patients (13–18 years) was analyzed. AutoML with Improved Harmony Search Optimization (IHSO) processed features: age, fracture classification, surgery duration, blood loss, and 24 h-postoperative labs (coagulation triad/D-dimer/CRP). Primary outcome: 90-day composite adverse events (DVT/infection/early callus formation disorder/reoperation). SHAP explained predictions.Results: Baseline characteristics were balanced between training and test sets (P > 0.05). The IHSO-optimized algorithm outperformed controls in 91.67% of CEC2022 benchmark functions. AutoML model performance significantly surpassed conventional methods: training set ROC-AUC: 0.9667, test set ROC-AUC: 0.9247 (PR-AUC: 0.8350). Decision curves demonstrated clinical net benefit across 6%–99% risk thresholds. Key feature importance ranked as: age > operative duration > fibrinogen > fracture classification > APTT > CRP > BMI > D-dimer. SHAP analysis revealed: 1) Increasing age significantly attenuates the risk contribution of surgery duration; 2) FIB >4.0 g/L + elevated CRP indicated coagulation-inflammation cascade; 3) AO-C type fractures carried highest risk.Conclusion: This AutoML model, validated through explainability techniques, confirms the core predictive value of age, operative duration, and coagulation-inflammation networks for adolescent tibial fracture risk management. Though requiring prospective validation, the three-tier warning system establishes a stepped framework for individualized intervention. Future studies should advance multicenter collaborations integrating dynamic monitoring indicators to optimize clinical applicability.

1 October 2019 in World Neurosurgery
Verified
Journal Article
Closed access
BZBin Zhang
Bin Zhang
RYRan Yan
Ran Yan
JLJun Lu
Jun Lu
ZMZhenzhen Ma
Zhenzhen Ma
XZXuhui Zhang
Xuhui Zhang
JSJian-Gang Shi
Jian-Gang Shi